ESMO 2022

ESMO 2022
September 09-13, 2022
Paris, France

European Society of Medical Oncology Congress 2022.

Explore more information for Gilead Oncology therapies
Results (7)

A Phase 2, Randomized Study of Magrolimab with Bevacizumab and FOLFIRI in Previously Treated Patients with Advanced Inoperable Metastatic Colorectal Cancer (mCRC)

Overall Survival (OS) Results from the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC) in Patients with HR+/HER2- Metastatic Breast Cancer (mBC)

ASCENT-04/KEYNOTE-D19: Phase 3 study of sacituzumab govitecan plus pembrolizumab (pembro) vs treatment of physician’s choice (TPC) plus pembro in first-line programmed death-ligand 1-positive (PD-L1+) metastatic triple-negative breast cancer (mTNBC)

ASCENT-03: Phase 3 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in first-line (1L) metastatic triple-negative breast cancer (mTNBC)

Unmet need in heavily pre-treated patients with HR+/HER2- metastatic breast cancer (mBC) in the US: A ConcertAI analysis

Health-related quality of life (HRQoL) in the phase 3 TROPiCS-02 trial of sacituzumab govitecan (SG) vs chemotherapy in HR+/HER2- metastatic breast cancer (MBC)

Sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status in the phase 3 TROPiCS-02 study